FORA vs INFU vs HCAT vs OPRX vs OMCL

For growth investors, Forian Inc.

(FORA) is the stronger pick with 50. 1% revenue growth year-over-year, versus 1. 5% for Health Catalyst, Inc. (HCAT). OptimizeRx Corporation (OPRX) offers the better valuation at 18. 4x trailing P/E (5. 3x forward), making it the more compelling value choice. Analysts rate InfuSystem Holdings, Inc. (INFU) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, OptimizeRx Corporation (OPRX) is the cheapest at 18.

4x versus Omnicell, Inc. at 881. 5x. On forward P/E, OptimizeRx Corporation is actually cheaper at 5. 3x.

Over the past 5 years, InfuSystem Holdings, Inc.

(INFU) delivered a total return of -50. 2%, compared to -96. 8% for Health Catalyst, Inc. (HCAT). Over 10 years, the gap is even starker: INFU returned +240. 1% versus HCAT's -95. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Forian Inc.

(FORA) is the lower-risk stock at 0. 21β versus OptimizeRx Corporation's 2. 16β — meaning OPRX is approximately 929% more volatile than FORA relative to the S&P 500. On balance sheet safety, Forian Inc. (FORA) carries a lower debt/equity ratio of 0% versus 70% for Health Catalyst, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Forian Inc.

(FORA) is pulling ahead at 50. 1% versus 1. 5% for Health Catalyst, Inc. (HCAT). On earnings-per-share growth, the picture is similar: InfuSystem Holdings, Inc. grew EPS 181. 8% year-over-year, compared to -121. 7% for Health Catalyst, Inc.. Over a 3-year CAGR, FORA leads at 22. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

OptimizeRx Corporation (OPRX) is the more profitable company, earning 4.

7% net margin versus -57. 2% for Health Catalyst, Inc. — meaning it keeps 4. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OPRX leads at 11. 0% versus -11. 6% for HCAT. At the gross margin level — before operating expenses — OPRX leads at 63. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 5.

3x forward P/E versus 44. 8x for Health Catalyst, Inc. — 39. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 241. 4% to $17. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Forian Inc.

(FORA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 21)). OptimizeRx Corporation (OPRX) carries a higher beta of 2. 16 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FORA: -90. 5%, OPRX: +53. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: FORA is a small-cap high-growth stock; INFU is a small-cap quality compounder stock; HCAT is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock; OMCL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.